Brief: Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
03/06/2024 21:04
June 3 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O :
* ELEDON PRESENTS UPDATED DATA FROM ONGOING PHASE 1B TRIAL
EVALUATING TEGOPRUBART FOR PREVENTION OF REJECTION IN KIDNEY
TRANSPLANTATION
* ELEDON PHARMACEUTICALS-RESULTS SHOWED THAT TEGOPRUBART IS
GENERALLY SAFE AND WELL TOLERATED IN PATIENTS UNDERGOING DE NOVO
KIDNEY TRANSPLANTATION
Source text for Eikon: ID:nGNX2KbJ3R
Further company coverage: ELDN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial